首页> 外文期刊>Ophthalmology >One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients.
【24h】

One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients.

机译:日本患者年龄相关性黄斑变性和息肉样脉络膜血管病的光动力治疗一年结局。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To determine the prevalence of polypoidal choroidal vasculopathy (PCV) in Japanese patients presumed to have age-related macular degeneration (AMD) and compare 1-year outcomes after photodynamic therapy between PCV and choroidal neovascularization secondary to AMD. DESIGN: Prospective interventional study. PARTICIPANTS: Ninety-three consecutive patients (93 eyes) met the inclusion criteria: at least 50 years old, best-corrected visual acuity (VA) of 34 to 73 on the Early Treatment Diabetic Retinopathy Study (ETDRS) letter chart, a subfoveal lesion 5400 mum or smaller in greatest linear dimension (GLD) on fluorescein angiography (FA), and eligibility for photodynamic therapy. METHODS: Indocyanine green angiography was performed in all participants, and PCV and AMD were differentiated, treated with photodynamic therapy, and the patients observed for 1 year. The GLD was determined by FA for AMD and by indocyanine green angiography for PCV, and the diameter of the laser spot size was chosen, with an extra 1000 microm added to the GLD. Photodynamic therapy was repeated if leakage occurred on FA at 3-month follow-up visits. MAIN OUTCOME MEASURES: Prevalence of PCV at baseline and visual and angiographic changes 1 year after photodynamic therapy in PCV and AMD. RESULTS: Using indocyanine green angiography, 36 eyes (39%) were diagnosed with PCV and 54 eyes (58%) with choroidal neovascularization secondary to AMD. The median change in VA using the ETDRS letter score from baseline to 1 year was -7.0 in AMD eyes and +8.0 in PCV eyes (Mann-Whitney rank sum test; P<0.001). The VA improved (> or =15 letters) in AMD and PCV by 6% and 25%, respectively, and decreased (> or =15 letters) by 31% and 8%, respectively. Fluorescein leakage stopped at 1 year in 86% of PCV and 61% of AMD eyes (P = 0.031). Polypoidal choroidal vasculopathy recurred in 2 PCV eyes (5.6%), and a new PCV lesion developed in 1 PCV eye (2.8%) and 2 AMD eyes (3.7%) on indocyanine green angiography at 1 year. CONCLUSION: The prevalence of PCV meeting the treatment criteria for photodynamic therapy for presumed AMD is high in Japanese patients. Photodynamic therapy is more efficacious for PCV than for AMD, which may explain the good results in Japanese patients. Further study should assess the long-term clinical results.
机译:目的:确定年龄与年龄有关的黄斑变性(AMD)的日本患者中的息肉样脉络膜血管病(PCV)的患病率,并比较光动力治疗后PCV与继发于AMD的脉络膜新血管形成之间的一年结局。设计:前瞻性干预研究。参与者:连续93例患者(93眼)符合纳入标准:至少50岁,在早期糖尿病性视网膜病变研究(ETDRS)字母图上显示的最佳矫正视力(VA)为34至73,有一个小凹下病变荧光素血管造影(FA)的最大线性尺寸(GLD)为5400毫米或更小,并且符合光动力疗法的资格。方法:对所有参与者进行吲哚菁绿血管造影,对PCV和AMD进行区分,进行光动力治疗,并观察患者1年。 GLD由FA(对于AMD)和吲哚菁绿色血管造影(对于PCV)确定,并选择激光光斑尺寸的直径,并在GLD中添加额外的1000微米。如果在3个月的随访中FA发生渗漏,则重复光动力疗法。主要观察指标:光动力疗法治疗PCV和AMD后1年,基线时PCV的患病率以及视觉和血管造影变化。结果:使用吲哚菁绿血管造影,诊断为PCV的36眼(39%)和继发于AMD的脉络膜新血管形成为54眼(58%)。从基线到1年,使用ETDRS字母评分的VA的中位变化在AMD眼中为-7.0,在PCV眼中为+8.0(Mann-Whitney秩和检验; P <0.001)。在AMD和PCV中,VA分别提高(>或= 15个字母)6%和25%,而在(>或= 15个字母)之下分别降低31%和8%。 86%的PCV和61%的AMD眼在1年时荧光素泄漏停止(P = 0.031)。 1年时,吲哚花青绿色血管造影在2支PCV眼(5.6%)中复发了息肉样脉络膜血管病变,在1支PCV眼(2.8%)和2支AMD眼(3.7%)中出现了新的PCV病变。结论:在日本患者中,达到假定的AMD光动力疗法治疗标准的PCV患病率很高。光动力疗法对PCV比对AMD更有效,这可以解释日本患者的良好疗效。进一步的研究应评估长期临床结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号